• Mon news: Novartis Kisqali breast cancer trial. ESMO news: Bayer, Bristol Myers, Regeneron and more. Biosecure Act fallout. Boston Scientific/Silk Road merger. See more on our front page

Billed as $3.6 billion deal to disrupt cancer, collaboration ends with thud